Fintel reports that on January 31, 2025, JMP Securities initiated coverage of Astria Therapeutics (NasdaqGM:ATXS) with a Market Outperform recommendation. Analyst Price Forecast Suggests 244.82% ...
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors ...
JMP Securities initiated coverage on Astria Therapeutics (NASDAQ: ATXS), assigning a Market Outperform rating and setting a ...
JMP Securities analyst Jonathan Wolleben initiated coverage of Astria Therapeutics (ATXS) with an Outperform rating and $26 price target ...